Formerly known as Anhui Jinnemai Pharmaceutical Technology Co., Ltd, the main business is clinical research of new drugs, the national class 1 new drug injection of rat nerve growth factor (NGF), access to the Ministry of Science and Technology of the State SMEs Innovation Fund of 1.5 million yuan and the local government to support the +750,000 yuan incentive.
In 2006, the original company was canceled, the establishment of Anhui Shengtai Pharmaceutical Science and Technology Co., Ltd, the main business is still the clinical trials of new drugs, 1 project in the development of new drugs in the category of biologics (recombinant human interferon ω) + chemical and Chinese medicine clinical trials, as well as the technical registration, declaration of the "Certificate of New Drugs" and "Production Approval".
In 2010, the company was changed to Anhui Medivic Dacheng Pharmaceutical Technology Co., Ltd (Medivic), with the main business of clinical trials of new drugs (CRO), completing phase I/II/III clinical studies of a major national research project of a new class of biologics 1 drug (recombinant human interferon omega), completing phase I/II clinical studies of a new class of biologics 1 drug (recombinant human interferon omega), completing phase I/II clinical studies of 4-6 classes of drugs, completing phase I/II clinical studies of 4-6 classes of drugs, and completing phase I/II clinical studies of 4-6 classes of drugs. The company has also completed phase I/II clinical research on a new drug (recombinant human interferon ω), and 21 items of chemical drugs in categories 4-6 and 14 items of traditional Chinese medicines in categories 4-9, all of which have been successfully transformed into scientific and technological achievements.
(Left: Wang Chuan-sheng? (Right: Chen Wei)
Photo of a meeting
In the past experience of entrepreneurship, y appreciate the hardship of scientific research, but dedicated research, diligently pursuing the joy of achieving results, the important thing is to bring to the people can be cured of disease and relief of pain, rehabilitation of the body's social responsibility, the main pharmaceutical research and development of the laboratory research, clinical research, production and manufacturing of the three major processes of the intermediary link in the clinical trial, the clinical trial is also a key factor in determining whether a new drug can be used in the market. Clinical trials are also a key link in determining whether a new drug can be marketed, the company has been fruitful in this business segment, highly recognized by the CFDA and CDE, and highly appreciated by enterprises in the transformation of results!
Beginning in 2009, the company increased its business segment, medical equipment, hospital clinical promotion, mainly imported equipment and high-quality consumables, 2012 began to increase the business of imported technology registration, overseas drugs, medical devices, health food, cosmetics, as the continuation of imported registrations today, has been approved by the part of the drugs and health food, and its products in the national investment.
Technological innovation is fundamental, the product is the foundation, marketing is the king, to solve the market sales difficulties, to compete for the terminal product market share, all customers and consumers think, to the platform of the development strategy; in the name of the company's legal person shares and natural person shares invested in the creation of Hefei Yishenghui Health Science and Technology Company Limited --- Yishenghui new retail platform.
Acquired the CQCS "China Health New Retail Demonstration Platform", obtained the small program and APP software copyright, copyright.
Currently, we have 62 invention and appearance patents, 17 software copyrights, and have been an innovative enterprise in Hefei City for 3 consecutive years!
In 2019, Anhui Province, the first batch of "Science and Technology Innovation Board" listed enterprises, enterprise abbreviation: Medical Union Dacheng, stock code: 612106.